In the Era of BCR-ABL1 Inhibitors, are We Closing the Survival Gap between Allogeneic Hematopoietic Cell Transplantation and Chemotherapy for Ph+ ALL in First Complete Remission?

Commentary on “Allogeneic stem cell transplantation versus tyrosine kinase inhibitors combined with chemotherapy in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia” by Wang J, et al.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research